Identifying heart issues in patients with neuroendocrine tumors
Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications
This study is testing if certain blood markers can help find heart problems in patients with neuroendocrine tumors, with or without carcinoid syndrome, to see how their heart health changes over time.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06321692 on ClinicalTrials.gov |
What this trial studies
This study evaluates cardiac biomarkers in patients diagnosed with neuroendocrine tumors (NET), with or without carcinoid syndrome, at the European Institute of Oncology. The main focus is on measuring blood levels of myocardial injury markers, hemodynamic markers, and fibrosis markers to assess cardiac involvement and its progression over time. Patients will undergo baseline assessments, including blood sampling and cardiological evaluations, followed by regular re-evaluations every three months and echocardiograms every six months.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with metastatic neuroendocrine tumors with or without carcinoid syndrome.
Not a fit: Patients under 18 years old or those with pre-existing heart disease prior to their NET diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of cardiac complications in patients with neuroendocrine tumors.
How similar studies have performed: Other studies have shown promise in using biomarkers for cardiac assessment in cancer patients, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients diagnosed with metastatic NET with or without carcinoid referred to the Unit of Neuroendocrine Tumors of European Institute of Oncology Exclusion Criteria: * age \<18 years * patients diagnosed with heart disease prior to diagnosis of NET
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Daniela Cardinale, MD — European Institute of Oncology
- Study coordinator: Daniela Cardinale, MD
- Email: daniela.cardinale@ieo.it
- Phone: +39 0257489748
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.